Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies

Laura Belver; Adolfo A Ferrando

doi:10.1158/2159-8290.CD-15-0095

Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies

Cancer Discov. 2015 Mar;5(3):234-6. doi: 10.1158/2159-8290.CD-15-0095.

Authors

Laura Belver¹, Adolfo A Ferrando²

Affiliations

¹ Institute for Cancer Genetics, Columbia University, New York, New York.
² Institute for Cancer Genetics, Columbia University, New York, New York. Department of Pathology, Columbia University Medical Center, New York, New York. Department of Pediatrics, Columbia University Medical Center, New York, New York. af2196@columbia.edu.

Abstract

Kleppe and colleagues use detailed cytokine profiling analyses to investigate the role of aberrant proinflammatory cytokine secretion in the pathogenesis of myeloproliferative neoplasms. Their analyses implicate constitutive activation of STAT3 in both malignant and nonmalignant bone marrow cell populations as a driver of aberrant cytokine secretion and as a cellular target mediating the therapeutic activity of ruxolitinib.

Publication types

Comment

MeSH terms

Animals
Cell Transformation, Neoplastic / metabolism*
Humans
Janus Kinases / metabolism*
Myeloproliferative Disorders / metabolism*
STAT Transcription Factors / metabolism*
Signal Transduction*

Substances

STAT Transcription Factors
Janus Kinases

Grants and funding

R01 CA120196/CA/NCI NIH HHS/United States